4D Molecular Therapeutics Inc Cash Flow-to-Debt Ratio
4D Molecular Therapeutics Inc cash flow-to-debt ratio. 4D Molecular Therapeutics Inc (FDMT) has a Cash Flow-to-Debt Ratio of 0.47x as of December 2025, meaning its operating cash flow of $28.55 Million could theoretically repay 0% of its total liabilities ($61.05 Million) in one year. Check earnings quality score of 4D Molecular Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of 4D Molecular Therapeutics Inc (2017–2025)
Cash flow-to-debt ratio of 4D Molecular Therapeutics Inc from 2017 to 2025. Historical debt coverage capacity for 4D Molecular Therapeutics Inc across 9 annual periods. Check 4D Molecular Therapeutics Inc (FDMT) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
4D Molecular Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2017–2025)
4D Molecular Therapeutics Inc cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for 4D Molecular Therapeutics Inc. For the full cash flow conversion analysis, see FDMT cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.79x | $-109.08 Million | $61.05 Million | ▲ +33.9% |
| 2024 | -2.70x | $-134.59 Million | $49.78 Million | ▼ -14.4% |
| 2023 | -2.36x | $-75.79 Million | $32.06 Million | ▲ +16.8% |
| 2022 | -2.84x | $-86.69 Million | $30.51 Million | ▼ -41.3% |
| 2021 | -2.01x | $-69.13 Million | $34.38 Million | ▼ -26.2% |
| 2020 | -1.59x | $-50.91 Million | $31.94 Million | ▼ -469.6% |
| 2019 | -0.28x | $-36.71 Million | $131.20 Million | ▼ -114.4% |
| 2018 | -0.13x | $-16.25 Million | $124.56 Million | ▼ -174.3% |
| 2017 | 0.18x | $8.24 Million | $46.91 Million | — |